Therapy To Target Amyloid Also Reduces Tau In Alzheimer's Disease

Main Category: Alzheimer's / Dementia
Article Date: 14 Jul 2010 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


A potential new treatment for Alzheimer's may target not one but two hallmarks associated with the disease, claims new research presented at the International Conference of Alzheimer's Disease (ICAD).

Scientists have claimed a treatment called bapineuzumab reduces the amount of tau and amyloid - two important proteins in Alzheimer's - in people with the disease.

The treatment is currently in phase III testing and is being developed as an antibody to beta-amyloid plaques associated with Alzheimer's. In this latest research, scientists looked at the impact of bapineuzumab on tau in the cerebrospinal fluid of 46 people with Alzheimer's disease. They found an overall trend towards a reduction in levels of tau.

Other research presented at ICAD also highlights further advancements towards a better understanding of tau.

Alzheimer's Society comment:

'Any advancement towards a new treatment for Alzheimer's will provide hope for hundreds of thousands of people living with the disease. Bapineuzumab is a promising therapy that is currently in the final stages of testing. If successful it could be licensed and available within 5 years.'

'Importantly, this study shows that a treatment targeting plaques in the brains of people with Alzheimer's can also reduce the protein tau, another key hallmark of Alzheimer's. However, if we are to make the most of this new evidence and progress towards treatments we need much more research. One in three people over 65 will die with dementia yet dementia research is drastically underfunded. We must invest now.'

Professor Clive Ballard
Director of Research

Research reference: 'Immunotherapy with bapineuzumab lowers csf tau protein levels in patients with Alzheimer's disease' by Kaj Blennow et al

Note

ICAD is the world's leading forum on dementia research. Run by Alzheimer's Association, it will this year be taking place in Hawaii from Sunday 11 July to Thursday 15 July.

Source:
Alzheimer's Society

Article adapted by Medical News Today from original press release.
Visit our alzheimer's / dementia section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Alzheimer's Society. "Therapy To Target Amyloid Also Reduces Tau In Alzheimer's Disease." Medical News Today. MediLexicon, Intl., 14 Jul. 2010. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/194644.php>

APA
Alzheimer's Society. (2010, July 14). "Therapy To Target Amyloid Also Reduces Tau In Alzheimer's Disease." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/194644.php.

Please note: If no author information is provided, the source is cited instead.


Alzheimer's / Dementia

What is Dementia?

The word dementia comes from the Latin de meaning "apart" and mens from the genitive mentis meaning "mind". Dementia is the progressive deterioration in cognitive function - the ability to process thought (intelligence). Read more...

What Is Alzheimer's Disease?

Alzheimer's disease is a progressive neurologic disease of the brain leading to the irreversible loss of neurons and the loss of intellectual abilities, including memory and reasoning. Read more...

Most Popular Articles



Follow Our Alzheimer's News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Alzheimer's / Dementia Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »